ABSK021

DRUG4 trials

Sponsors

Abbisko Therapeutics Co. Ltd., Abbisko Therapeutics Co, Ltd

Conditions

Healthy SubjectsNeoplasmsTenosynovial Giant Cell TumorcGvHD

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

RecruitingNCT04192344

Abbisko Therapeutics Co, LtdNeoplasms, Tenosynovial Giant Cell Tumor

Start: 2020-01-20End: 2026-12-31Target: 276Updated: 2026-03-19

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

CompletedNCT06322706

Abbisko Therapeutics Co, LtdHealthy Subjects

Start: 2024-03-22End: 2024-11-01Updated: 2025-02-18

Phase 2

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitationNCT06186804

Abbisko Therapeutics Co, LtdcGvHD

Start: 2023-05-30End: 2026-12-30Target: 64Updated: 2024-08-12

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor

RecruitingCTIS2023-503245-58-00

Abbisko Therapeutics Co. Ltd.Tenosynovial Giant Cell Tumor

Start: 2023-10-04Target: 30Updated: 2025-05-13

Related Papers

Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.

Journal of Clinical Oncology2026-05-27

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Blood2024-11-052 citations

Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.

Journal of Clinical Oncology2023-06-019 citations

First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-014 citations

Abstract LB329: A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma

Cancer Research2023-04-141 citations